Our top pick for
IMAX Corporation is an entertainment business based in the US. IMAX Corporation shares (IMAX) are listed on the NYSE and all prices are listed in US Dollars. IMAX Corporation employs 673 staff and has a trailing 12-month revenue of around USD$205.3 million.
|52-week range||USD$6.01 - USD$22.015|
|50-day moving average||USD$19.2379|
|200-day moving average||USD$15.3364|
|Wall St. target price||USD$22.09|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.494|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing IMAX Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IMAX Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IMAX Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, IMAX Corporation shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
IMAX Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.09. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IMAX Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
IMAX Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$8.1 million.
The EBITDA is a measure of a IMAX Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$205.3 million|
|Gross profit TTM||USD$216.4 million|
|Return on assets TTM||-5.64%|
|Return on equity TTM||-21.3%|
|Market capitalisation||USD$1.3 billion|
TTM: trailing 12 months
There are currently 3.0 million IMAX Corporation shares held short by investors – that's known as IMAX Corporation's "short interest". This figure is 15.8% down from 3.6 million last month.
There are a few different ways that this level of interest in shorting IMAX Corporation shares can be evaluated.
IMAX Corporation's "short interest ratio" (SIR) is the quantity of IMAX Corporation shares currently shorted divided by the average quantity of IMAX Corporation shares traded daily (recently around 793538.28125). IMAX Corporation's SIR currently stands at 3.84. In other words for every 100,000 IMAX Corporation shares traded daily on the market, roughly 3840 shares are currently held short.
However IMAX Corporation's short interest can also be evaluated against the total number of IMAX Corporation shares, or, against the total number of tradable IMAX Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IMAX Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 IMAX Corporation shares in existence, roughly 50 shares are currently held short) or 0.0758% of the tradable shares (for every 100,000 tradable IMAX Corporation shares, roughly 76 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IMAX Corporation.
Find out more about how you can short IMAX Corporation stock.
We're not expecting IMAX Corporation to pay a dividend over the next 12 months.
IMAX Corporation's shares were split on a 2:1 basis on 27 May 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your IMAX Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IMAX Corporation shares which in turn could have impacted IMAX Corporation's share price.
Over the last 12 months, IMAX Corporation's shares have ranged in value from as little as $6.01 up to $22.015. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while IMAX Corporation's is 1.8292. This would suggest that IMAX Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company that specializes in digital and film-based motion picture technologies worldwide. It offers cinematic solution comprising proprietary software, theater architecture, intellectual property, and equipment. The company offers Digital Re-Mastering (DMR), a proprietary technology that digitally enhances the image resolution, visual clarity, and sound quality of motion picture films for projection on IMAX screens; IMAX premium theater systems to exhibitor customers through sales, long-term leases, and joint revenue sharing arrangements; film post-production services; and camera and other miscellaneous items rental services, as well as distributes documentary films; and owns and operates IMAX theaters. It also designs, manufactures, installs, sells, and leases IMAX theater projection system equipment; maintains IMAX theater projection system equipment in the IMAX theater network; distributes and licenses original content, virtual reality, IMAX home entertainment, and others; and sells or leases its theater systems to theme parks, private home theaters, tourist destination sites, fairs, and expositions, as well as engages in the after-market sale of projection system parts and 3D glasses. The company markets its theater systems through a direct sales force and marketing staff. It owns or otherwise has rights to trademarks and trade names, which include IMAX, IMAX Dome, IMAX 3D, IMAX 3D Dome, Experience It in IMAX, The IMAX Experience, An IMAX Experience, An IMAX 3D Experience, IMAX DMR, DMR, IMAX nXos, and Films To The Fullest. As of March 31, 2020, the company had a network of 1,616 IMAX theater systems comprising 1,526 commercial multiplexes, 14 commercial destinations, and 76 institutional facilities operating in 81 countries and territories. IMAX Corporation was founded in 1967 and is headquartered in Mississauga, Canada.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.